{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-controlled-study-of-imc-f106c-plus-nivolumab-versus-nivolumab-regimens-in-hla-a0201-positive-participants-with-previously-untreated-advanced-melanoma-prism-mel-301\/#breadcrumbitem"}]}